IT vendor offers a service to measure TMF capabilities
Where do pharma companies stand regarding their use of automated systems for monitoring trial master files (TMFs), the documentation collected during a clinical trial? Veeva Systems’ (Pleasanton, CA) service offers some objective measures of how research organizations are managing the process, according to Jason Methia, director of Vault eTMF strategy at the company. TMFs are set alongside a clinical trial management system (CTMS) at many trial sponsors and contract research organizations (CROs), but many are still paper-based or managed off of spreadsheets or home-grown, nonstandard systems. (There is a TMF Reference Model, developed by a project team of the Drug Information Assn.; version 3 was published last June.)
Veeva’s maturity model ranks TMF development on a 1-5 scale; broadly speaking, from completely manual to completely electronic (eTMF). A key value of eTMFs, says Methia, is the ability to establish an audit trail for changes in trial progress and record-keeping. Regulatory agencies like FDA or the UK’s MHRA periodically conduct audits of the TMF when an application for drug approval is presented to them,” notes Methia. “A compilation performed by MHRA in 2014 found that 35% of TMFs had auditability problems.” He says that, based on surveys and studies performed by Veeva, most pharma companies rate around 2.54 on the 1-5 scale. At an average of level 3 and above, TMFs are being actively managed, with draft documents being checked in and out of the systems, electronic signatures appended to files and other aspects of an electronically based system, he says.
Veeva, a leader in cloud-based IT systems for life sciences, set up its Vault platform for storing various types of documents in a secure, trackable manner, and developed Veeva Clinical (of which its eTMF product is a part) in 2012. The cloud-based aspect allows for ease of access for trial sponsors, CROs and investigators sites and according to recent customer surveys, the volume of paper being handled is being reduced by a third to half currently, with more improvements ahead. The Veeva eTMF is said to fully support the DIA TMF Reference Model.
Access to the eTMF Maturity Model, which can be evaluated in a self-service mode, is here.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.